Colitis and colorectal cancer

Digestive Diseases

Volumn 30, Issue 5, 2012, Pages 469-476

  Foersch, Sebastian ^a   Waldner, Maximilian J ^a   Neurath, Markus F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Colitis associated carcinoma; Colorectal cancer; Inflammatory bowel disease

Indexed keywords

APC PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN P53; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; URSODEOXYCHOLIC ACID; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SURGERY; CARCINOGENESIS; CHEMOPROPHYLAXIS; CHROMOENDOSCOPY; COLITIS; COLITIS ASSOCIATED CARCINOMA; COLONOSCOPY; COLORECTAL CARCINOMA; CONFOCAL LASER MICROSCOPY; CROHN DISEASE; DIAGNOSTIC ACCURACY; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; MAINTENANCE THERAPY; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; COLITIS; COLORECTAL NEOPLASMS; ENDOSCOPY; HUMANS; MICE; MUTATION; RISK FACTORS;

EID: 84868105443     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000341692     Document Type: Article

References (70)

1. Kirsner JB: Historical aspects of inflammatory bowel disease. J Clin Gastroenterol 1988; 10: 286-297.
2. Crohn B, Rosenberg H: The sigmoidoscopic picture of chronic ulcerative colitis (nonspecific). Am J Med Sci 1925; 170: 220-228.
3. Jess T, Gamborg M, Matzen P, Munkholm P, Sørensen TIA: Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005; 100: 2724-2729.
4. Gillen CD, Andrews HA, Prior P, Allan RN: Crohn's disease and colorectal cancer. Gut 1994; 35: 651-655.
5. Ekbom A, Helmick C, Zack M, Adami HO: Ulcerative colitis and colorectal cancer: a population-based study. N Engl J Med 1990; 323: 1228-1233.
6. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO: Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56: 48-54.
7. Eaden JA, Abrams KR, Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535.
8. Lashner BA, Turner BC, Bostwick DG, Frank PH, Hanauer SB: Dysplasia and cancer complicating strictures in ulcerative colitis. Dig Dis Sci 1990; 35: 349-352.
9. Velayos FS, Loftus EV, Jess T, Harmsen WS, Bida J, Zinsmeister AR, et al: Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006; 130: 1941-1949.
10. Lukas M: Inflammatory bowel disease as a risk factor for colorectal cancer. Dig Dis 2010; 28: 619-624.
11. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532.
12. Nuako KW, Ahlquist DA, Mahoney DW, Schaid DJ, Siems DM, Lindor NM: Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology 1998; 115: 1079-1083.
13. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
14. Tarmin L, Yin J, Harpaz N, Kozam M, Noordzij J, Antonio LB, et al: Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res 1995; 55: 2035-2038.
15. Fogt F, Vortmeyer AO, Goldman H, Giordano TJ, Merino MJ, Zhuang Z: Comparison of genetic alterations in colonic adenoma and ulcerative colitis-associated dysplasia and carcinoma. Hum Pathol 1998; 29: 131-136.
16. Burmer GC, Rabinovitch PS, Haggitt RC, Crispin DA, Brentnall TA, Kolli VR, et al: Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 1992; 103: 1602-1610.
17. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, et al: Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000; 60: 3333-3337.
18. Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, et al: Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994; 107: 369-378.
19. Xavier RJ, Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434.
20. Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, et al: Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci USA 2003; 100: 143-148.
21. Cravo ML, Albuquerque CM, Salazar de Sousa L, Glória LM, Chaves P, Dias Pereira A, et al: Microsatellite instability in non-neoplastic mucosa of patients with ulcerative colitis: effect of folate supplementation. Am J Gastroenterol 1998; 93: 2060-2064.
22. Itzkowitz SH: Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am 2006; 35: 553-571.
23. Amit S, Ben-Neriah Y: NF-kappaB activation in cancer: a challenge for ubiquitination-and proteasome-based therapeutic approach. Semin Cancer Biol 2003; 13: 15-28.
24. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-296.
25. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R: Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118: 229-241.
26. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, et al: TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004; 21: 491-501.
27. Chung Y-C, Chang Y-F: Significance of inflammatory cytokines in the progression of colorectal cancer. Hepatogastroenterology 2003; 50: 1910-1913.
28. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, et al: Blocking TNFalpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008; 118: 560-570.
29. Kim YJ, Hong KS, Chung JW, Kim JH, Hahm KB: Prevention of colitis-associated carcinogenesis with infliximab. Cancer Prev Res (Phila) 2010; 3: 1314-1333.
30. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
31. Costa C, Incio J, Soares R: Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 2007; 10: 149-166.
32. Yoo S-A, Kwok S-K, Kim W-U: Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediators Inflamm 2008; 2008: 129873.
33. Scaldaferri F, Vetrano S, Sans M, Arena V, Straface G, Stigliano E, et al: VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009; 136: 585-595.e5.
34. Waldner MJ, Wirtz S, Jefremow A, Warntjen M, Neufert C, Atreya R, et al: VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med 2010; 207: 2855-2868.
35. Jänne PA, Mayer RJ: Chemoprevention of colorectal cancer. N Engl J Med 2000; 342: 1960-1968.
36. Raju R, Cruz-Correa M: Chemoprevention of colorectal cancer. Dis Colon Rectum 2006; 49: 113-124, discussion 124-125.
37. Velayos FS, Terdiman JP, Walsh JM: Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 1345-1353.
38. Ishikawa TO, Herschman HR: Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis 2010; 31: 729-736.
39. Collins PD, Mpofu C, Watson AJ, Rhodes JM: Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006:CD000279.
40. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, et al: Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004; 53: 1813-1816.
41. Bernstein CN, Shanahan F, Weinstein WM: Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994; 343: 71-74.
42. Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, et al: DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992; 103:1611-1620.
43. Blackstone MO, Riddell RH, Rogers BH, Levin B: Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in longstanding ulcerative colitis: an indication for colectomy. Gastroenterology 1981; 80: 366-374.
44. Ullman T, Odze R, Farraye FA: Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon. Inflamm Bowel Dis 2009; 15: 630.
45. Hoffman A, Kagel C, Goetz M, Biesterfeld S, Galle PR, Neurath MF, et al: High definition colonoscopy (HD plus) with i-scan function allows to recognize and characterize flat neoplastic changes as precisely as chro-mo endoscopy. Gastrointest Endosc 2008; 67:AB125-AB125.
46. Kudo S, Tamura S, Nakajima T, Yamano H, Kusaka H, Watanabe H: Diagnosis of colorectal tumorous lesions by magnifying endoscopy. Gastrointest Endosc 1996; 44: 8-14.
47. Neumann H, Mönkemüller K, Günther C, Atreya R, Vieth M, Neurath MF: Advanced endoscopic imaging for diagnosis of Crohn's disease. Gastroenterol Res Pract 2012; 2012: 301541.
48. Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, Kanzler S, et al: Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124: 880-888.
49. Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB, Talbot IC: Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 2004; 53: 256-260.
50. Wu L, Li P, Wu J, Cao Y, Gao F: The diagnostic accuracy of chromoendoscopy for dysplasia in ulcerative colitis: meta-analysis of six randomized controlled trials. Colorectal Dis 2012; 14: 416-420.
51. Pellisé M, López-Cerón M, Rodríguez de Miguel C, Jimeno M, Zabalza M, Ricart E, et al: Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. Gastrointest Endosc 2011; 74: 840-848.
52. Hoffman A, Sar F, Goetz M, Tresch A, Mudter J, Biesterfeld S, et al: High definition colonoscopy combined with i-scan is superior in the detection of colorectal neoplasias compared with standard video colonoscopy: a prospective randomized controlled trial. Endoscopy 2010; 42: 827-833.
53. Kiesslich R: Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology 2004; 127: 706-713.
54. Kiesslich R, Goetz M, Lammersdorf K, Schneider C, Burg J, Stolte M, et al: Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology 2007; 132: 874-882.
55. Hurlstone DP, Thomson M, Brown S, Tiffin N, Cross SS, Hunter MD: Confocal endomicroscopy in ulcerative colitis: differentiating dysplasia-associated lesional mass and adenoma-like mass. Clin Gastroenterol Hepatol 2007;5: 1235-1241.
56. Foersch S, Kiesslich R, Waldner MJ, Delaney P, Galle PR, Neurath MF, et al: Molecular imaging of VEGF in gastrointestinal cancer in vivo using confocal laser endomicroscopy. Gut 2010; 59: 1046-1055.
57. Goetz M, Ziebart A, Foersch S, Vieth M, Waldner MJ, Delaney P, et al: In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor. Gastroenterology 2010; 138: 435-446.
58. Neurath MF, Kiesslich R: Molecular detection of CD44v6 on aberrant crypt foci by confocal laser endoscopy. Endoscopy 2010; 42(suppl 2):E314-E315.
59. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J: Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 145-153.
60. Lindberg B, Persson B, Veress B, Ingelman-Sundberg H, Granqvist S: Twenty years' colonoscopic surveillance of patients with ulcerative colitis: detection of dysplastic and malignant transformation. Scand J Gastroenterol 1996; 31: 1195-1204.
61. Pardi DS, Loftus EV, Kremers WK, Keach J, Lindor KD: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-893.
62. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, et al: Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134: 89-95.
63. Ikegami T, Matsuzaki Y: Ursodeoxycholic acid: mechanism of action and novel clinical applications. Hepatol Res 2008; 38: 123-131.
64. Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VAC, et al: High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011; 106: 1638-1645.
65. Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, et al: Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008; 6: 1212-1217, quiz 1176.
66. Baumgart DC: Endoscopic surveillance in Crohn's disease and ulcerative colitis: who needs what and when? Dig Dis 2011; 29(suppl 1):32-35.
67. Ullman TA, Itzkowitz SH: Intestinal inflammation and cancer. Gastroenterology 2011; 140: 1807-1816.
68. Galon J, Costes A, Sanchez-Cabo F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964.
69. Baumgart DC: Recognition and appropriate management of dysplasia-associated lesions or masses in inflammatory bowel disease-experience does matter. Gastrointest Endosc 2007; 66: 530-532.
70. Farraye FA, Odze RD, Eaden J, Itzkowitz SH: AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138: 746-774.